- Report
- August 2025
- 224 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- August 2025
- 181 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- August 2025
- 196 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- August 2025
- 392 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- August 2025
- 193 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- August 2025
- 213 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- January 2025
- 175 Pages
Global
From €4070EUR$4,490USD£3,521GBP
- Clinical Trials
- July 2025
- 80 Pages
Global
From €1813EUR$2,000USD£1,569GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2720EUR$3,000USD£2,353GBP
- Clinical Trials
- July 2025
- 280 Pages
Global
From €2720EUR$3,000USD£2,353GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1813EUR$2,000USD£1,569GBP
- Drug Pipelines
- April 2025
- 80 Pages
Global
From €1813EUR$2,000USD£1,569GBP
- Clinical Trials
- April 2025
- 180 Pages
Global
From €2266EUR$2,500USD£1,961GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1360EUR$1,500USD£1,176GBP
- Drug Pipelines
- April 2025
- 50 Pages
Global
From €1360EUR$1,500USD£1,176GBP
- Report
- March 2025
- 450 Pages
Global
From €4533EUR$5,000USD£3,921GBP
- Report
- April 2025
- 147 Pages
Global
From €2719EUR$2,999USD£2,352GBP
- Report
- August 2025
- 371 Pages
Global
From €5303EUR$5,850USD£4,588GBP
- Report
- May 2025
- 185 Pages
Global
From €4080EUR$4,500USD£3,529GBP
- Report
- May 2025
- 190 Pages
Global
From €4080EUR$4,500USD£3,529GBP

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases.
Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments.
The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more